We are live on ! Find out more
KRBP

Kiromic BioPharma, Inc. Common Stock
KRBP

Delisted

KRBP was delisted on the 13th of September, 2023.

Back to rankings

15 hedge funds and large institutions have $11.9M invested in Kiromic BioPharma, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

257% more capital invested

Capital invested by funds: $3.34M → $11.9M (+$8.57M)

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

36% more funds holding

Funds holding: 11 → 15 (+4)

Holders
15
Holders Change
+4
Holders Change %
+36.36%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
5
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KC
Kepos Capital
New York
+$6.41M
2
SM
Sabby Management
Florida
+$4.18M
3
ACM
Altium Capital Management
New York
+$2.79M
4
1CM
1492 Capital Management
Wisconsin
+$1.44M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$910K

Top Sellers

Rank Fund Capital Flow
1
ZCA
Zeke Capital Advisors
Pennsylvania
-$252K
2
Citadel Advisors
Citadel Advisors
Florida
-$203K
3
UBS Group
UBS Group
Switzerland
-$16K
4
RAM
Redmond Asset Management
Virginia
-$752
Name Holding Trade Value Shares
Change 		Change in
Stake
KC
1
Kepos Capital
New York
$3.69M +$6.41M +25,567 New
SM
2
Sabby Management
Florida
$2.41M +$4.18M +16,684 New
1CM
3
1492 Capital Management
Wisconsin
$1.72M +$1.44M +5,736 +93%
ACM
4
Altium Capital Management
New York
$1.6M +$2.79M +11,116 New
Vanguard Group
5
Vanguard Group
Pennsylvania
$574K +$910K +3,630 +1,046%
M
6
Murchinson
Ontario, Canada
$481K +$836K +3,333 New
IP
7
Intellectus Partners
California
$360K +$307K +1,225 +96%
WAM
8
Warberg Asset Management
Illinois
$303K +$527K +2,100 New
FIA
9
FNY Investment Advisers
New York
$288K +$501K +2,000 New
RAM
10
Redmond Asset Management
Virginia
$218K -$752 -3 -0.2%
SC
11
Shay Capital
New York
$120K +$209K +833 New
ZCA
12
Zeke Capital Advisors
Pennsylvania
$81K -$252K -1,004 -64%
BlackRock
13
BlackRock
New York
$46K +$37.6K +150 +88%
Morgan Stanley
14
Morgan Stanley
New York
$15K +$15K +60 +128%
Citadel Advisors
15
Citadel Advisors
Florida
– -$203K -724 Closed
UBS Group
16
UBS Group
Switzerland
– -$16K -58 Closed

KRBP Hedge Fund Activity: Q2 2021 in Review

15 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Kiromic BioPharma, Inc. Common Stock (KRBP) for Q2 2021, worth a combined $11.9M — up 257% from $3.34M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new KRBP positions and 3 closed out — a net gain of 4 holders — while 5 added to existing stakes and 2 trimmed.

The largest buyer was Kepos Capital, opening a new position worth an estimated $6.41M. The largest seller was Zeke Capital Advisors, cutting an estimated $252K.

  • 15 institutional investors held Kiromic BioPharma, Inc. Common Stock (KRBP) as of Q2 2021, up from 11 in Q1 2021.
  • Funds reported $11.9M of Kiromic BioPharma, Inc. Common Stock stock for Q2 2021, up 257% quarter-over-quarter.
  • 7 funds opened new Kiromic BioPharma, Inc. Common Stock positions in Q2 2021 and 3 closed out, a net change of +4 holders.
  • The largest Kiromic BioPharma, Inc. Common Stock buyer in Q2 2021 was Kepos Capital, an estimated $6.41M added.
  • The largest Kiromic BioPharma, Inc. Common Stock seller in Q2 2021 was Zeke Capital Advisors, an estimated $252K sold.

Based on aggregated 13F filings for Q2 2021.